Genetically Engineered Biomaterials: Using Science to Mimic Nature

Biomaterials are naturally occurring materials, derived either from plants or animals. Due to their superior properties, these materials find uses in many industries. Synthetic biologists are constantly researching ways to mimic these materials as well as ways to improve on them. In this article, we will discuss why it is important to develop synthetic versions of nature’s building blocks, and about the companies that have succeeded in doing so. Finally, we will learn how CRISPR is contributing to the world of biomaterials.

Spotlight

VeritasGenetics

Veritas Genetics is the leader in consumer genetics. We are an energetic start-up, recently named as one of MIT’s 50 Smartest Companies in 2016, with a strong pulse and mission as well as a passion for empowering people to live longer and healthier lives.

OTHER ARTICLES
Medical

2022 U.S. Market Research Report with COVID-19 Forecasts2

Article | July 14, 2022

The global biotechnology market is expected to grow at a compound annual growth rate (CAGR) of 13.9 percent from 2022 to 2030, with a value estimated at USD 1,023.92 billion in 2021. The market is being propelled by strong government support in the form of initiatives aimed at modernizing the regulatory framework, improving approval processes and reimbursement policies, and standardizing clinical studies. The growing presence of personalized medicine and an increasing number of orphan drug formulations are opening up new avenues for biotechnology applications and driving the influx of emerging and innovative biotechnology companies, which is driving market revenue even further. The 2022 Biotech Research and Development Market Research Report is one of the most comprehensive and in-depth assessments of the industry in the United States, containing over 100 data sets spanning the years 2013 to 2026. This Kentley Insights report contains historical and forecasted market size, product lines, profitability, financial ratios, BCG matrix, state statistics, operating expense details, organizational breakdown, consolidation analysis, employee productivity, price inflation, pay bands for the top 20 industry jobs, trend analysis and forecasts on companies, locations, employees, payroll, and much more. Companies in the Biotech Research and Development industry are primarily engaged in biotechnology research and experimental development. Biotechnology research and development entails the investigation of the use of microorganisms and cellular and bimolecular processes to create or modify living or non-living materials. This biotechnology research and development may result in the development of new biotechnology processes or prototypes of new or genetically altered products that can be replicated, used, or implemented by various industries. This report was created using the findings of extensive business surveys and econometrics. The professionals follow reports with accurate and apt information on market sizing, benchmarking, strategic planning, due diligence, cost-cutting, planning, understanding industry dynamics, forecasting, streamlining, gap analysis, and other ana

Read More
MedTech

AI and Biotechnology: The Future of Healthcare Industry

Article | October 7, 2022

Artificial intelligence has grasped the foundation in biotech. It can have the most innovative impact on biotechnology. AI has already established its presence in our day-to-day life. AI has made the existence of self-driving cars possible. Likewise, the benefits and quality that it can contribute to biotech can also be felt. With AI, bio technicians will be able to enhance virtual screening, overlook preliminary datasets from clinics, and decipher an enormous amount of information. It can also help in improving the medication process by gathering and analyzing every bit of information. The Significance of AI in Biotechnology In the past few years, the application of artificial intelligence in the biotechnology industry has shifted from being sci-fi to sci-fact. A vast number of biotech companies like Deep Genomics are adopting AI for making data-driven decisions and use analytics tools to work efficiently. Unlike the AI robots in sci-fi that are ready to take over the world. AI designed for biotech has been designed to solve certain problems or complete a bunch of tasks by using automated algorithms. The aim of AI technology for biotech is to collect insights along with hidden patterns from large amounts of data. All the different industries of biotech including agriculture, animal, medical, industrial, and bioinformatics are gradually being affected by artificial intelligence. Moreover, the biotech industry is realizing that AI enables them some of the important strength to their business, including: Expanding accessibility Cost-effectiveness Critical predictions Efficient decision-making Research centers like PwC have also estimated output of $15.7 trillion by 2030 solely with AI contribution in industries. A survey revealed that about 44% of life science experts are using AI for R&D activities, as well. Use of AI in Biotechnology Altering Biomedical and Clinical Data So far the most developed use of AI is its ability to read voluminous data records and interpret them. It can prove to be a life-save for bio technicians who would have to examine that much data from research publications by themselves for the validation of their hypothesis. With the help of AI, clinical studies of patients will also become easier as all the examination reports and prescriptions will be stored in one place for cross-reference. Furthermore, it will also help in blending and fetching data into usable formats for analysis. Test Result Prediction Through trial and error, AI along with machine learning can help in predicting the response of the patient to certain drugs to provide more effective outcomes. Drug Design & Discovery AI plays a vital role whether it’s designing a new molecule or identifying new biological targets. It helps in identifying and validating drugs. It reduces the cost and time spent on the entire drug trial process and reaches the market. Personalized Medications for Rare Diseases With the combination of body scan results, patients’ body and analytics, AI can also help in detecting dangerous diseases at an early stage. Improving Process of Manufacturing To improve the process of manufacturing in biotechnology, AI offers a wide range of opportunities. It controls quality, reduces wastage, improves useability, and minimizes the designing time. Moving Towards AI-Enhanced Biotech Future Ever since the concept of artificial intelligence has arrived, being curious by nature, humans have started working towards achieving this goal. It has been growing at a fast pace while showing unbelievable growth and achievements at times. In comparison to the traditional methods used in the biotechnology industry, AI-based methods seem more reliable and accurate. In the upcoming years, it will show its success by improving the quality of health people have. You can also develop your AI-based application or know more about it by taking IT consultations.

Read More
MedTech

Biotech in 2022

Article | July 11, 2022

The robust global channel of more than, 800 gene and cell curatives presently in trials will produce clinical readouts in 2022, revealing what lies ahead for advanced curatives. The impact will be felt in 2022, no matter how you slice it. Eventually, how well industry and non-supervisory bodies unite to produce new frameworks for advanced therapies will shape the year 2022 and further. Pacific Northwest talent will continue to contribute to the advancement of gene and cell curatives in both the short and long term, thanks to its deep pool of ground-breaking scientific developers, entrepreneurial directorial leadership, largely skilled translational scientists, and endured bio manufacturing technicians. We may see continued on-life science fund withdrawal from biotech in 2021, but this can be anticipated as a strong comeback in 2022 by biotech industry, backed by deep-pocketed life science investors who are committed to this sector. A similar investment, combined with pharma's cash-heavy coffers, can result in increased junction and acquisition activity, which will be a challenge for some but an occasion for others. Over the last five years, investment interest in Seattle and the Pacific Northwest has grown exponentially, from Vancouver, British Columbia, to Oregon. The region's explosive portfolio of new biotech companies, innovated out of academic centres, demonstrates the region's growing recognition of scientific invention. This created a belief that continued, especially because Seattle's start-ups and biotech enterprises are delivering on their pledge of clinical and patient impact. Talent and staffing will continue to be difficult to find. It's a CEO's market, but many of these funds' return, and are not rising in proportion to the exorbitant prices they're paying to enter deals. This schism has become particularly pronounced in 2021. Hence, everyone in biotech is concerned about reclamation and retention.

Read More

2 Small-Cap Biotech Stocks You Haven't Heard of, But Should Know About

Article | April 17, 2020

With everything that's going on with the COVID-19 pandemic, many healthcare companies have grabbed plenty of spotlight during these challenging times. At the same time, a number of otherwise promising businesses have slipped under the radar. That's especially true for small-cap biotech stocks that aren't actively involved in developing tests, vaccines or treatments for COVID-19. Vaccine developers, protective equipment producers, and healthcare service providers are all attracting plenty of attention during this pandemic, but there are just as many promising biotech stocks that aren't involved in these areas. Here are two such companies that you might have missed, but they deserve a spot on your watch list.

Read More

Spotlight

VeritasGenetics

Veritas Genetics is the leader in consumer genetics. We are an energetic start-up, recently named as one of MIT’s 50 Smartest Companies in 2016, with a strong pulse and mission as well as a passion for empowering people to live longer and healthier lives.

Related News

AquaBounty considers labelling genetically modified salmon

CBC.CA | April 16, 2019

The U.S.-based company that's about to start the commercial production of genetically modified salmon in P.E.I. says it's considering labelling the product as such. However, it's not clear what exactly AquaBounty Technologies intends to tell consumers about the fish, which are modified with a growth hormone gene to make them grow faster. "We are considering our labelling options and working with potential customers to determine the appropriate approach," a spokesperson for AquaBounty said in a statement sent to CBC News. The genetically modified salmon, produced in indoor tanks in Rollo Bay, P.E.I., will become the first genetically engineered food animal to be sold in Canadian grocery stores. Environment Canada and Health Canada have given their approval, but it's up to the latter to determine whether products require labelling. "Health Canada requires labelling for food products where clear, scientifically established health risks or significant nutritional changes have been identified that can be mitigated through labelling," said spokesperson Maryse Durette. 'Safe and nutritious,' Health Canada says After a four-year study, the federal agency has determined the genetically modified salmon to be "safe and nutritious" and therefore no labelling is required. AquaBounty's most recent statement on labelling is news to Sylvain Charlebois, a Dalhousie University professor in food distribution and policy. "I did encourage AquaBounty to reconsider its policy around transparency and risk communication," he said Sunday on CBC Radio's Maritime Connection. "It is a pleasant surprise to me because I do think that the industry is starting to realize how important it is to connect with the public more so than ever before to get that social licence." AquaBounty Technologies is planning to grow 250 tonnes of its AquAdvantage salmon in Rollo Bay. The fish will be on the market in late 2020.

Read More

AquaBounty considers labelling genetically modified salmon

CBC.CA | April 16, 2019

The U.S.-based company that's about to start the commercial production of genetically modified salmon in P.E.I. says it's considering labelling the product as such. However, it's not clear what exactly AquaBounty Technologies intends to tell consumers about the fish, which are modified with a growth hormone gene to make them grow faster. "We are considering our labelling options and working with potential customers to determine the appropriate approach," a spokesperson for AquaBounty said in a statement sent to CBC News. The genetically modified salmon, produced in indoor tanks in Rollo Bay, P.E.I., will become the first genetically engineered food animal to be sold in Canadian grocery stores. Environment Canada and Health Canada have given their approval, but it's up to the latter to determine whether products require labelling. "Health Canada requires labelling for food products where clear, scientifically established health risks or significant nutritional changes have been identified that can be mitigated through labelling," said spokesperson Maryse Durette. 'Safe and nutritious,' Health Canada says After a four-year study, the federal agency has determined the genetically modified salmon to be "safe and nutritious" and therefore no labelling is required. AquaBounty's most recent statement on labelling is news to Sylvain Charlebois, a Dalhousie University professor in food distribution and policy. "I did encourage AquaBounty to reconsider its policy around transparency and risk communication," he said Sunday on CBC Radio's Maritime Connection. "It is a pleasant surprise to me because I do think that the industry is starting to realize how important it is to connect with the public more so than ever before to get that social licence." AquaBounty Technologies is planning to grow 250 tonnes of its AquAdvantage salmon in Rollo Bay. The fish will be on the market in late 2020.

Read More

Events